Treatment of peripheral attacks in patients with hereditary angioedema

Patients with diagnosis of hereditary angioedema who have a moderate to severe attack of peripheral edema will receive 30 mg of a bradykinin inhibitor via three 1ml subcutaneous injections to assess response of angioedema. Patients will be closely monitored for four hours and may receive a second dose at four hours if patient did not achieve a complete response. Patient will be closely monitored for another four hours. Prior to discharge patient will receive an electric diary to record symptoms and instructed of its use. Patient will return to the clinic for three follow-up visits.

You may be eligible to participate in this study if:

• You have documented decrease of C4 and C1  esterase inhibitor levels
• You are 10 years of age or older
• You (or patient guardian) are willing to sign an informed consent form
• You can report to study site no later than eight hours following patient recognition of onset of an attack of HAE considered to be at least moderately severe

This is a partial list of eligibility requirements. To inquire about your eligibility, call contact number provided.